[1]中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京: 人民卫生出版社,2010.[2]WHO. 世界卫生组织耐药结核病规划管理指南(2008年紧急修订版). 北京: 中国疾病预防控制中心结核病防治临床中心,2008.[3]戴丽华, 黄文华. 福建省莆田市荔城区新发涂阳肺结核患者强化期末痰涂片结果分析. 疾病监测,2011,26(12):949-951.[4]World Health Organization. WHO report 2011: global tuberculosis control. Geneva: World Health Organization, 2011.[5]World Health Organization. WHO global tuberculosis report 2013. Geneva: World Health Organization, 2013.[6]World Health Organization. Multidrug-resistant TB (MDR-TB): 2013[M/OL].Geneva: World Health Organization, 2013[2014-10-10]. http://www.who.int/tb/challenges/mdr/MDR_TB_FactSheet.[7]Suárez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, 2002,359(9322):1980-1989.[8]Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study.Eur Respir J, 2006,28(5):980-985.[9]郝晓晖,唐神结,刘一典,等. 初治耐多药肺结核临床疗效及其转归队列分析研究. 中华医学会结核病学分会2011年学术会议论文汇编, 2011:7.[10]洪峰,高志东,李波,等. 北京市耐多药肺结核控制5年结果分析. 中国防痨杂志, 2013,35(9):706-710.[11]刘国标, 张丽好, 何霞, 等. 广州市初治涂阳肺结核患者治疗2个月末痰涂片不阴转原因探讨. 中国防痨杂志,2005,27(6):360-363.[12]Brust JC, Berman AR, Zalta B, et al. Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa. PloS One, 2013,8(9):e73975.[13]Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.Int J Tuberc Lung Dis,1998,2(11):877-884.[14]Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis, 2008,47(4):496-502.[15]Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?Eur Respir J, 2008,31(4):904-905.[16]Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PloS One, 2014, 9(4): e94890.[17]Prammananan T, Arjratanakool W, Chaiprasert A, et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis, 2005,9(2):216-219.[18]Wang D, Yang C, Kuang T, et al. Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Jpn J Infect Dis, 2010,63(5):368-371.[19]Rodriguez M, Monedero I, Caminero JA, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.Int J Tuberc Lung Dis, 2013,17(4):520-525.[20]Janssen S, Padanilam X, Louw R, et al. How many sputum culture results do we need to monitor multidrug-resistant-tuberculosis (MDR-TB) patients during treatment? J Clin Microbiol, 2013,51(2):644-646. |